Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Wrap Technologies, Golar LNG, BioMarin Pharmaceuticals, and Garrett Motion and Encourages Investors to Contact the Firm
28 oct. 2020 17h00 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
DEADLINE ALERT for WRTC, GLNG, GTX, GTXMQ, and BMRN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
27 oct. 2020 12h00 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Oct. 27, 2020 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GoHealth, Wrap Technologies, Golar LNG, and BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
21 oct. 2020 17h00 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Golar LNG, BioMarin Pharmaceuticals, Garrett Motion, and Peabody Energy and Encourages Investors to Contact the Firm
14 oct. 2020 18h00 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Wrap Technologies, Golar LNG, BioMarin Pharmaceuticals, and Garrett Motion and Encourages Investors to Contact the Firm
07 oct. 2020 20h00 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
BMRN STOCK ALERT: Zhang Investor Law Announces Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN
06 oct. 2020 12h47 HE
|
Zhang Investor Law P.C.
NEW YORK, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between...
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
29 sept. 2020 18h00 HE
|
Bragar Eagel & Squire
NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United...
BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12 déc. 2016 08h29 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has initiated a global Phase 3 study for vosoritide, an analog of...
BioMarin Announces Third Quarter 2016 Financial Results
27 oct. 2016 16h03 HE
|
BioMarin Pharmaceutical Inc.
- Third Quarter 2016 Total BioMarin Revenues Increase 34% Year over Year to $280 million - Vimizim Net Product Revenues Increase 25% Year over Year to $81 million in the Third Quarter 2016 - Kuvan...
BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting
19 oct. 2016 17h01 HE
|
BioMarin Pharmaceutical Inc.
Highest Dose (30 µg/kg/day) Shows Approximately 50% Increase in Mean Annualized Growth Velocity, Comparable with 15 µg/kg/day dose Consistent Safety Profile at High Dose Findings Support 15...